Several Key Management Changes Announced
NEW YORK, March 5 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb
Company (NYSE: BMY) today announced that the company's Board of Directors
has elected Jean-Marc Huet senior vice president and chief financial
officer, effective March 31, 2008. In this role, Mr. Huet will be
responsible for directing and managing the company's fiscal operations, as
well as the global financial operations of the organization and its
subsidiaries. Andrew Bonfield, executive vice president and chief financial
officer, will remain in that role until Mr. Huet's arrival. He will leave
the company after a period of transition to seek new career opportunities.
"The Board and I wish to express our gratitude to Andrew Bonfield, who
led the transformation of our financial organization over the last six
years, and the strengthening of our internal controls following a period of
significant challenges," said Jim Cornelius, chairman and chief executive
officer. "He instituted new processes and procedures to modernize the
company's financial reporting and streamlined the global finance
organization to deliver superior financial support. We are pleased he has
agreed to stay with the company for a period of time to support the
transition to Jean-Marc, whom Andrew helped identify as a potential
successor in 2007 when he began to discuss with me new challenges to
further develop his career."
Prior to joining Bristol-Myers Squibb, Mr. Huet served as chief
financial officer at Royal Numico N.V. in Amsterdam. He is credited with
initiating and developing Numico's acquisition strategy within the
consolidating baby food sector and its resulting acquisition by Groupe
Danone. Prior to joining Royal Numico, N.V., he was an executive director,
Investment Banking Services, at Goldman Sachs International in London. He
also spent several years at Clement Trading in Milan, Italy, as a
commercial manager. Mr. Huet has a B.A. degree from Dartmouth College and
an MBA from INSEAD.
In addition, Lamberto Andreotti, currently executive vice president and
chief operating officer, Worldwide Pharmaceuticals, will also assume
responsibility for Mead Johnson and ConvaTec, and has been named executive
vice president and chief operating officer of Bristol-Myers Squibb.
"Lamberto and Elliott Sigal, M.D., Ph.D., executive vice president and
chief scientific officer, continue to help shape and drive the
transformation of Bristol-Myers Squibb to a next-generation BioPharma
leader," said Cornelius. "As we continue to evolve, Lamberto and Elliott,
together with the members of our Management Council, will play vital roles
in shaping the Bristol-Myers of the future.
"We are also announcing several important internal promotions and
changes of responsibility of senior management to allow us to focus on key
elements of our next generation BioPharma strategy," Cornelius added.
John Celentano, formerly president of the Health Care Group, has been
appointed senior vice president, Strategy and Productivity Transformation,
a new position at the company. He will assume responsibility for Strategy,
Corporate and Business Development, and Information Management and Global
Shared Services and will continue to lead the company's Productivity
Transformation Initiative;
Brian Daniels, M.D., senior vice president, Global Development, will
join the Management Council, the company's most senior leadership group.
Together with Elliott Sigal, Dr. Daniels will drive the company's focus on
science and medicine as a central strategy of the next-generation BioPharma
vision;
Anthony McBride, Ph.D., has been promoted to senior vice president of
Human Resources. Dr. McBride, who will also join the Management Council,
succeeds Stephen Bear, who will retire later this month after a long and
distinguished career at the company;
Robert Zito, senior vice president and chief communications officer,
will assume oversight of the BMS Foundation, adding John Damonti, president
of the Foundation, to his leadership team.
Bristol-Myers Squibb Company is a global biopharmaceutical and related
health care products company whose mission is to extend and enhance human
life.
SOURCE Bristol-Myers Squibb Company
 back to top
Related links:
http://www.bms.com
CONTACT:
Media, Tracy Furey, Communications,
+1-609-252-3208, tracy.furey@bms.com, or Rebecca Goldsmith,
Communications, +1-609-252-4551, rebecca.goldsmith@bms.com;
Investors, John Elicker, Investor Relations, +1-212-546-3775,
john.elicker@bms.com, or Suketu Desai, Investor Relations,
+1-609-252-5796, suketu.desai@bms.com, all of Bristol-Myers
Squibb Company
|
